Trifluridine/Tipiracil and ATR-CHK1-WEE1 pathway inhibition against TP53-mutant esophageal cancer as synthetic lethality

被引：0
|
作者：
Kikuchi, Osamu [1 ,2 ]
Trang Nguyen [1 ,3 ]
Ohashi, Shinya [3 ,4 ]
Muto, Manabu [2 ,3 ]
机构：
[1] Kyoto Univ, Ctr Canc Immunotherapy & Immunobiol, Kyoto, Japan
[2] Kyoto Univ, Clin Bioresource Ctr, Kyoto, Japan
[3] Kyoto Univ, Med Oncol, Kyoto, Japan
[4] Kyoto Univ, Preempt Med & Lifestyle Related Dis Res Ctr, Kyoto, Japan
来源：
CANCER SCIENCE | 2025年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E-3003
引用
收藏
页码：1342 / 1342
页数：1
相关论文
共 50 条
  • [21] Single-nucleus transcriptomics of IDH1-and TP53-mutant glioma stem cells displays diversified commitment on invasive cancer progenitors
    Gulaia, Valeriia
    Shmelev, Mikhail
    Romanishin, Aleksander
    Shved, Nikita
    Farniev, Vladislav
    Goncharov, Nikolay
    Biktimirov, Arthur
    Vargas, Irene Lisa
    Khodosevich, Konstantin
    Kagansky, Alexander
    Kumeiko, Vadim
    SCIENTIFIC REPORTS, 2022, 12 (01):
  • [22] Isogenic CRISPR anchor screens identified actionable nodes to CHK1/2 inhibitor prexasertib in TP53 mutant cancer
    Teng, Teng
    Paik, Stephen
    Zhao, Shan-Chuan
    Choi, Ashley
    Lombardo, Steven A.
    Liu, Shangtao
    Meier, Samuel R.
    Yu, Yi
    Anderson, Jannik N.
    Huang, Alan
    Li, Fang
    Pan, Xuewen
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [23] MUS81 Inhibition Enhances the Anticancer Efficacy of Talazoparib by Impairing ATR/CHK1 Signaling Pathway in Gastric Cancer
    Wang, Tao
    Zhang, Peng
    Li, Chengguo
    Liu, Weizhen
    Shen, Qian
    Yang, Lei
    Xie, Gengchen
    Bai, Jie
    Li, Ruidong
    Tao, Kaixiong
    Yin, Yuping
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [24] PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness
    Gralewska, Patrycja
    Gajek, Arkadiusz
    Marczak, Agnieszka
    Mikula, Michal
    Ostrowski, Jerzy
    sliwinska, Agnieszka
    Rogalska, Aneta
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (24) : 1 - 20
  • [25] Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells
    Origanti, S.
    Cai, S-R
    Munir, A. Z.
    White, L. S.
    Piwnica-Worms, H.
    ONCOGENE, 2013, 32 (05) : 577 - 588
  • [26] Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells
    S Origanti
    S-r Cai
    A Z Munir
    L S White
    H Piwnica-Worms
    Oncogene, 2013, 32 : 577 - 588
  • [27] Author Correction: Single-nucleus transcriptomics of IDH1- and TP53-mutant glioma stem cells displays diversified commitment on invasive cancer progenitors
    Valeriia Gulaia
    Mikhail Shmelev
    Aleksander Romanishin
    Nikita Shved
    Vladislav Farniev
    Nikolay Goncharov
    Arthur Biktimirov
    Irene Lisa Vargas
    Konstantin Khodosevich
    Alexander Kagansky
    Vadim Kumeiko
    Scientific Reports, 13
  • [28] Identification of a rhodium(III) complex as a Wee1 inhibitor against TP53-mutated triple-negative breast cancer cells
    Yang, Guan-Jun
    Zhong, Hai-Jing
    Ko, Chung-Nga
    Wong, Suk-Yu
    Vellaisamy, Kasipandi
    Ye, Min
    Ma, Dik-Lung
    Leung, Chung-Hang
    CHEMICAL COMMUNICATIONS, 2018, 54 (20) : 2463 - 2466
  • [29] SYNTHETIC LETHALITY IN P53 MUTATED B-CELL MALIGNANCIES: CHK-1 INHIBITION AND DNA-PK INHIBITION EFFECT IN CELL LINES AND PRIMARY CLL CELLS
    Zemanova, J.
    Sebejova, L.
    Paruch, K.
    Hylse, O.
    Pospisilova, S.
    Mayer, J.
    Trbusek, M.
    HAEMATOLOGICA, 2013, 98 : 402 - 402
  • [30] Lutein inhibits tumor progression through the ATR/Chk1/p53 signaling pathway in non-small cell lung cancer
    Zhang, Si-yu
    Lu, You-yi
    He, Xin-liang
    Su, Yuan
    Hu, Fen
    Wei, Xiao-shan
    Pan, Min-jie
    Zhou, Qiong
    Yang, Wei-bing
    PHYTOTHERAPY RESEARCH, 2023, 37 (04) : 1260 - 1273
12345